To include your compound in the COVID-19 Resource Center, submit it here.

Two faces of myeloid

How Pionyr intends to enhance the antitumor immune response

Pionyr Immunotherapeutics Inc. has a pipeline of preclinical antibodies that could enable it to selectively deplete immunosuppressive myeloid cells from tumors without harming immune-stimulating myeloid cells.

Myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) can weaken antitumor immunity and limit efficacy of checkpoint therapies.

However, a 2014 Cancer Cell paper by founder Max Krummel and his colleagues at University of California San Francisco demonstrated that at least one subtype

Read the full 720 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE